The role of m6A and m6Am RNA modifications in the pathogenesis of diabetes mellitus

0573796 - FGÚ 2024 RIV CH eng J - Článek v odborném periodiku
Benák, Daniel - Benáková, Štěpánka - Plecitá-Hlavatá, Lydie - Hlaváčková, Markéta
The role of m6A and m6Am RNA modifications in the pathogenesis of diabetes mellitus.
Frontiers in Endocrinology. Roč. 14, July (2023), č. článku 1223583. ISSN 1664-2392. E-ISSN 1664-2392
Grant CEP: GA ČR(CZ) GJ19-04790Y; GA MŠMT(CZ) LX22NPO5104; GA ČR(CZ) GA22-11439S
Institucionální podpora: RVO:67985823
Klíčová slova: type 2 diabetes mellitus * T2DM * diabetes * RNA * epigenetics * epitranscriptomics * m6A * m6Am
Obor OECD: Physiology (including cytology)
Impakt faktor: 5.2, rok: 2022
Způsob publikování: Open access
https://doi.org/10.3389/fendo.2023.1223583

The rapidly developing research field of epitranscriptomics has recently emerged into the spotlight of researchers due to its vast regulatory effects on gene expression and thereby cellular physiology and pathophysiology. N6-methyladenosine (m6A) and N6,2’-O-dimethyladenosine (m6Am) are among the most prevalent and well-characterized modified nucleosides in eukaryotic RNA. Both of these modifications are dynamically regulated by a complex set of epitranscriptomic regulators called writers, readers, and erasers. Altered levels of m6A and also several regulatory proteins were already associated with diabetic tissues. This review summarizes the current knowledge and gaps about m6A and m6Am modifications and their respective regulators in the pathophysiology of diabetes mellitus. It focuses mainly on the more prevalent type 2 diabetes mellitus (T2DM) and its treatment by metformin, the first-line antidiabetic agent. A better understanding of epitranscriptomic modifications in this highly prevalent disease deserves further investigation and might reveal clinically relevant discoveries in the future.
Trvalý link: https://hdl.handle.net/11104/0344151